For Second Time, PhRMA and Hogan End Lobbying Ties

Updated 1:58 p.m.

Pharmaceutical Research and Manufacturers of America has dropped Hogan Lovells from its roster of lobbying firms. But it isn't the first time.

The PhRMA lobbying termination report Hogan filed with Congress on Monday was the second such document the firm has filed, according to congressional records that date to 1999.

Before it filed lobbying termination paperwork in 2007, the firm, then known as Hogan & Hartson, spent at least eight years advocating for the pharmaceutical industry's biggest trade group on international health and trade issues, among other matters.In 2009, Hogan started lobbying for PhRMA again on trade. That work ended in July.

Hogan partner Warren Maruyama had worked on the account since at least 1999. From 2007 to 2009, he was the general counsel of the Office of the U.S. Trade Representative.

PhRMA spokeswoman Jenni Brewer declined to comment. Maruyama wasn't immediately available for comment.

Hogan only received about $10,000 of the $14.3 million PhRMA doled out during the first three quarters of this year to a squadron of lobbyists from its own ranks and more than three dozen firms, including Akin Gump Strauss Hauer & Feld, Arnold & Porter and Covington & Burling.

Maruyama had been the only Hogan lobbyist on the PhRMA account since 2009. After pulling in $100,000 from PhRMA during the fourth quarter of 2009, Hogan received at most $40,000 every following quarter. During the last quarter Hogan lobbied for PhRMA, the group paid the firm less than $5,000 for its work related to the Trans-Pacific Partnership, a trade agreement between the United States, Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, South Korea and Vietnam.

From 1999 to 2007, Hogan took in at least $220,000 per year from PhRMA. But Maruyama received help at Hogan from three colleagues.